Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
1,257,751
-
Shares change
-
+437,762
-
Total reported value, excl. options
-
$15,005,952
-
Value change
-
+$4,350,610
-
Number of buys
-
23
-
Number of sells
-
-10
-
Price
-
$11.93
Significant Holders of GYRE THERAPEUTICS, INC. - COM (GYRE) as of Q2 2024
36 filings reported holding GYRE - GYRE THERAPEUTICS, INC. - COM as of Q2 2024.
GYRE THERAPEUTICS, INC. - COM (GYRE) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,257,751 shares
.
Largest 10 shareholders include BlackRock Inc. (499,489 shares), GEODE CAPITAL MANAGEMENT, LLC (259,807 shares), VANGUARD GROUP INC (231,641 shares), STATE STREET CORP (96,078 shares), NORTHERN TRUST CORP (32,700 shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (23,091 shares), WINTON GROUP Ltd (18,467 shares), Bank of New York Mellon Corp (18,266 shares), RENAISSANCE TECHNOLOGIES LLC (13,900 shares), and MARSHALL WACE, LLP (10,720 shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.